157 related articles for article (PubMed ID: 21591514)
21. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Klapdor R; Lamerz R; Nilsson O; Sturgeon C; Topolcan O
Eur J Cancer; 2003 Apr; 39(6):718-27. PubMed ID: 12651195
[TBL] [Abstract][Full Text] [Related]
22. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
23. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
24. Use of Biomarkers in Screening for Cancer.
Duffy MJ
Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
[TBL] [Abstract][Full Text] [Related]
25. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
26. Practice guidelines for tumor marker use in the clinic.
Sturgeon C
Clin Chem; 2002 Aug; 48(8):1151-9. PubMed ID: 12142367
[TBL] [Abstract][Full Text] [Related]
27. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
Haglund C; Roberts PJ; Jalanko H; Kuusela P
Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
[TBL] [Abstract][Full Text] [Related]
28. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
29. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract][Full Text] [Related]
30. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
[TBL] [Abstract][Full Text] [Related]
31. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.
Haglund C; Ylätupa S; Mertaniemi P; Partanen P
Br J Cancer; 1997; 76(6):777-83. PubMed ID: 9310245
[TBL] [Abstract][Full Text] [Related]
32. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
[TBL] [Abstract][Full Text] [Related]
33. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
Duffy MJ
Clin Chem; 2001 Apr; 47(4):624-30. PubMed ID: 11274010
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of tumor markers in oncology.
Jacobs EL; Haskell CM
Curr Probl Cancer; 1991; 15(6):299-360. PubMed ID: 1760927
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
37. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
38. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
[TBL] [Abstract][Full Text] [Related]
39. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
40. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma.
Lopez JB; Balasegaram M; Timor J; Thambyrajah V
Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
